Replies to post #125982 on Biotech Values

[heldnova]

In this old video posted on Yahoo today they talk about the triple therapy using Gemzar, Abraxane and the Hedgehog inhibitor, presumably the Curis drug, but the patient that they profiled who has survived 8 years only got two thirds of the treatment. Apparently they are referring to Gemzar and Abraxane without the Curis drug.

http://www.cbsnews.com/stories/2010/09/09/eveningnews/main6851091.shtml

Rick

[BTH]

vismodegib has failed a CRC trial, and that historically regimens that have been shown to improve response rates haven't necessarily demonstrated improved survival.

Entirely different class of cancer, and entirely different thesis on how to attack the disease.

The pancreatic study thesis is on cracking the shell (stroma) of the tumor allowing chemo-drugs to efficiently get "into" the tumor, instead of being "pushed out" (which is what seems to be happening with current therapies). The Hh, in theory, is supposed to not only weaken the shell, but also kill the stem cells that allow the tumor cells to rehabilitate.

To my knowledge, the CRC trial and the CRC itself, was never intended to do this.

We shall see, I suppose.

[BTH]

An article on Hh and exploring its role in pancreatic tumors.

Its from March.

http://www.boltinternational.com/2011/03/hedgehogs-at-asco-2011/